Patheon to acquire state-of-the-art manufacturing site

Company gains additional API capacity and major supply agreement with Roche

Under the terms of the purchase agreement, Patheon will acquire the site for an immaterial sum, plus the cost of associated inventory and spare parts. Patheon has also entered into a multi-year supply arrangement with Roche. Patheon expects the supply agreement to help defray the costs associated with running the site for the next few years while it adds new client work into the facility. Over time, Patheon expects the Florence facility to have a similar financial profile to its other sites in its drug substance segment.

Patheon will acquire a 1,100 acre, 300,000 square-foot facility with manufacturing capacity for API ranging from development to manufacturing services. With the addition of this site, the company expands its capacity for manufacturing highly potent compounds, and adds capabilities to support solid-state chemistry, micronization, and eventually, commercial spray drying.

“As the only end-to-end provider of pharma development and manufacturing services, Patheon is uniquely positioned to integrate this new site into our global network and quickly leverage the capabilities with existing and new clients,” said James Mullen, CEO of Patheon. “The company will benefit from the additional North American API capacity and adds a state-of-the-art facility with approximately 200 scientific and manufacturing professionals.”

The site features reactors ranging from 50-11,000 L producing multiple products simultaneously, fully compliant with all applicable regulations, such as cGMP safety and environmental standards. It will provide Patheon with a major US API operation capable of supporting products from clinical scale to commercial manufacturing and further enhances Patheon’s scientific and technical expertise.